ITOS - iTeos Therapeutics reports Q3 results November, 10 2021 04:07 PM iTeos Therapeutics Inc. iTeos Therapeutics (NASDAQ:ITOS): Q3 GAAP EPS of $1.86 Revenue of $104.3M Cash and cash equivalents of $899.8M as of September 30, 2021 Press Release For further details see: iTeos Therapeutics reports Q3 results